bluebird bio (BLUE) Q4 2024 earnings summary

Executive summary

• Commercialized three gene therapies: ZYNTEGLO, SKYSONA, and LYFGENIA, with FDA approvals in 2022 and 2023 for severe genetic diseases.

• Entered into a merger agreement with Beacon Parent Holdings, L.P. in February 2025, with a cash tender offer and contingent value rights, expected to close in H1 2025.

• Restructuring in September 2024 reduced workforce by 25% and aimed to cut cash operating expenses by 20% by Q3 2025.

• Ongoing risk of going concern; cash runway projected into Q2 2025, dependent on merger completion.

Financial highlights

• FY 2024 net loss: $240.7 million, compared to $211.9 million in FY 2023.

• FY 2024 revenue: $83.8 million (up from $29.5 million in 2023), driven by 37 product infusions (vs. 12 in 2023).

• Cost of product revenue: $89.4 million in 2024 (vs. $33.5 million in 2023), reflecting higher sales volume.

• Cash and cash equivalents at year-end 2024: $62.3 million; accumulated deficit: $4.5 billion.

• No gain from sale of priority review voucher in 2024 (vs. $92.9 million in 2023).

Outlook and guidance

• Cash expected to fund operations into Q2 2025 and through merger closing; failure to close merger may result in liquidation or bankruptcy.

• No new clinical trials planned in Europe; focus remains on U.S. commercialization.

• Ongoing cost-saving initiatives and deferred vendor payments to manage liquidity.